Introduction
============

Extranodal natural killer (NK)/T-cell lymphoma (NKTCL) is a distinctive clinicopathological entity of non-Hodgkin\'s lymphoma according to the World Health Organization (WHO) classification of lymphoid neoplasms \[[@b1-crt-2018-681]\]. The disease is much more common in Asian and Latin American populations, and mostly happens in middle-aged male, with clinical characteristics of necrosis, ulceration, and destructive lesion \[[@b1-crt-2018-681]\]. NKTCL shows typical pathological features of angiocentric lesion, vessel damage, and coagulative necrosis \[[@b1-crt-2018-681]\].

NKTCL mostly originate in the nasal cavity or other sites of the upper aerodigestive tract (NK/T-cell lymphoma of upper aerodigestive tract \[UAT-NKTCL\]), while it could also happen in diverse sites outside the UAT (NK/T-cell lymphoma of non-upper aerodigestive tract \[NUAT-NKTCL\]), such as the skin and soft tissue, gastrointestinal tract (GI tract), liver, spleen, testicle, lung, eye, adrenal gland, and so forth \[[@b2-crt-2018-681],[@b3-crt-2018-681]\]. Previous retrospective studies found obvious heterogeneity in aspects of clinical features, risk factors, treatment response and prognosis between UAT-NKTCL and NUAT-NKTCL \[[@b2-crt-2018-681]-[@b10-crt-2018-681]\]. According to the research, NUAT-NKTCL patients had more advanced clinical stage, more unfavorable prognostic factors, worse treatment response, and clinical outcomes compared with UAT-NKTCL patients. Thus, NKTCL was divided into two subtypes in the WHO classification of tumors of lymphoid tissues (2008): nasal NKTCL (including UAT-NKTCL beyond the nasal cavity) and extranasal NKTCL (excluding UAT-NKTCL).

Currently, treatment experience of NKTCL is based on previous researches of UAT-NKTCL. UAT-NKTCL is highly sensitive to radiation therapy, which is now the main treatment for patients with limited stage disease. Published literature found unsatisfactory results of anthracyclines-based chemotherapy regimens in UAT-NKTCL, but conversely, promising results of asparaginase (ASP)-containing chemotherapy regimens \[[@b11-crt-2018-681]-[@b13-crt-2018-681]\]. Due to the much lower incidence and limited clinical evidence, treatment modality for NUAT-NKTCL remains to be elucidated so far. A retrospective study containing 59 patients with NUAT-NKTCL in 2008 analyzed clinical data and emphasized the clinical heterogeneity in aspects of clinical features, prognostic factors, and survival in the anthracycline era \[[@b3-crt-2018-681]\]. Thus, we conducted this retrospective study in a cohort of 92 NUAT-NKTCL patients, aiming to analyze the clinical characteristics, prognostic factors, treatment, and survival of these patients in the non-anthracycline era.

Materials and Methods
=====================

1. Patient selection and staging evaluation
-------------------------------------------

We retrospectively reviewed the medical records patients who were diagnosed with NKTCL at Sun Yat-sen University Cancer Center between 2001 and 2017. The inclusion criteria for our study were as follows: (1) patients confirmedly diagnosed with NKTCL based on the WHO classification of lymphomas \[[@b1-crt-2018-681]\]; (2) complete follow-up data. The term UAT used in this study included the nasal cavity, Waldeyer's ring, hypopharynx, larynx, and oral cavity. And NUAT-NKTCL represents NKTCL that originates beyond these anatomical sites. In total of 757 NKTCL patients were identified, including 92 NUAT-NKTCL patients (12.2%) and 665 UAT-NKTCL patients (87.8%).

The initial clinical evaluation included the following: a complete history and physical examination; serum biochemistry, including serum lactate dehydrogenase (LDH) levels; a bone marrow examination; and magnetic resonance imaging and/or computed tomography of the head, neck, chest, abdomen, and pelvis. Additional baseline evaluations, including positron emission tomography-computed tomography and plasma Epstein-Barr virus DNA (EBV-DNA) copy number, were performed in selected patients if necessary. Clinical staging was performed based on the Ann Arbor staging system. The international prognostic index (IPI) and the prognostic index of natural killer lymphoma (PINK) were calculated for all patients at initial presentation.

2. Response criteria and statistical analysis
---------------------------------------------

Treatment response was assessed according to the response criteria for lymphomas from the International Harmonization Project on Lymphoma \[[@b14-crt-2018-681]\]. The overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause or the date of the last follow-up visit. The progression-free survival (PFS) was measured from the date of diagnosis to the date of disease progression, relapse, death from any cause, or the last follow-up visit. Categorical variables were compared using the chi-square tests or Fisher exact tests, while continuous variables were compared using the Mann-Whitney U tests. Survival analysis was performed by plotting the Kaplan-Meier survival curve, in which a log-rank test was used to detect a statistically significant difference. The Cox proportional hazard model was used for a univariate screen of all potential predictors of survival. Variables with statistical and clinical significance were included in the multivariate analysis using the stepwise forward Cox regression model. A two-sided p-value \< 0.05 was considered significant. The statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) ver. 24.0 software (IBM Corp., Armonk, NY).

3. Ethical statement
--------------------

The study was approved by the ethics committee of Sun Yat-sen University Cancer Center (No.YB-201812) and the informed consent for collection and publication of medical information was obtained from all study patients at their first visit to our hospital. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)), with the approval RDD number as RDDA2019001016.

Results
=======

1. Clinical characteristics
---------------------------

The clinical characteristics of the NUAT-NKTCL patients and UAT-NKTCL patients are presented in [Table 1](#t1-crt-2018-681){ref-type="table"}. Both NUAT-NKTCL and UAT-NKTCL exhibited a male predominance, with similar male to female ratios of 1.7:1 and 2.3:1, respectively. The median age of NUAT-NKTCL and UAT-NKTCL was 35 years (range, 1 to 79 years) and 43 years (range, 3 to 80 years), which was significantly different (p= 0.004). However, there were 12 (13.0%) and 82 (12.3%) patients older than 60 years in two groups, respectively, which was not significantly different (p=0.846).

Compared with UAT-NKTCL, more NUAT-NKTCL patients had a poor performance status (Eastern Cooperative Oncology Group \[ECOG\] score ≥ 2, 42.4% vs. 10.7%, p \< 0.001). More NUAT-NKTCL patients presented with involvement of regional lymph nodes (51.7% vs. 36.9%, p=0.008), involvement of distant lymph nodes (28.1% vs. 9.8%, p \< 0.001), two or more extranodal lesions (44.0% vs. 12.4%, p \< 0.001), involvement of bone marrow (11.0% vs. 2.0%, p \< 0.001), and elevated LDH levels (55.4% vs. 28.5%, p \< 0.001). Conversely, there were not significant differences between two groups in terms of presence of B symptoms, presence of hemophagocytosis, and detectable EBV DNA in blood. The median of Ki-67 index in NUAT-NKTCL patients was slightly higher than that in UAT-NKTCL patients (70% vs. 60%, p \< 0.001). The median value of baseline maximal standardized uptake value in positron emission tomography for primary lesion was similar in NUAT-NKT-CL and UAT-NKTCL patients (2.7 vs. 2.0, p=0.924). NUAT-NKTCL patients had more advanced stage (stage III/IV, 64.8% vs. 15.1%, p \< 0.001), higher IPI scores (50.0% vs. 12.5% with IPI ≥ 3, p \< 0.001), and higher PINK scores (36.3% vs. 1.7% with PINK ≥ 3, p \< 0.001), compared with UAT-NKTCL patients.

The most common site of primary lesions in NUAT-NKTCL was the skin and soft tissue (n=42, 45.7%), followed by the GI tract (n=18, 19.6%), and the eye and adnexa (n=14, 15.2%) ([Table 2](#t2-crt-2018-681){ref-type="table"}). Other sites of primary disease included the testicle and ovary (n=5, 5.4%), the spleen (n=4, 4.3%), the lung and trachea (n=2, 2.2%), the central nervous system (n=2, 2.2%), and the adrenal gland (n=2, 2.2%). The primary lesions were unable to be classified in three patients (3.3%) due to the extensive involvement of multiple systems at the initial presentation.

2. Treatment and response
-------------------------

The treatment modalities for NUAT-NKTCL patients depended on their physicians and considered, e.g., the patient's physical status, clinical presentation, and comorbidities. Initial treatment modalities for this cohort are summarized in [Table 2](#t2-crt-2018-681){ref-type="table"}. The primary treatment included chemotherapy (CT) alone (64 cases, 69.6%), CT followed by radiotherapy (RT; 19 cases, 20.7%), RT followed by CT (3 cases, 3.3%), sandwich chemoradiation (4 cases, 4.3%), and supportive care alone (2 cases, 2.2%). RT was applied to 46.9% (15/32) of limited-stage (stage I/II) patients but only 18.6% (11/59) of advanced-stage patients, which was significantly different (p \< 0.001). Eighty-four point six percent of patients (n=22) receiving RT had their primary tumor located in skin and soft tissue, and eye and its adnexa.

Chemotherapy regimens varied during the study period depending upon the treating physicians ([S1 Table](#SD1-crt-2018-681){ref-type="supplementary-material"}). The most frequently used regimens included L-asparaginase (L-ASP) or pegaspargase/gemcitabine/oxaliplatin (GELOX/PGEMOX) in 29 patients (32.2%), cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in 10 patients (11.1%), etoposide/doxorubicin/vincristine/cyclophosphamide/pre dnisone (EPOCH) in 15 patients (16.7%), CHOP plus L-ASP (CHOP-L) in seven patients (7.8%), and miscellaneous regimens in 29 patients (32.2%). In summary, ASP was administered as part of the chemotherapy in 62 of 90 patients (68.9%). Details in dosage of chemotherapeutic regimens were formerly reported \[[@b15-crt-2018-681]\]. The median number of chemotherapy cycles was 4 (range, 0 to 12). The clinical characteristics of NUAT-NKTCL patients treated with ASP-containing and ASP-absent chemotherapy regimens were compared in [S2 Table](#SD2-crt-2018-681){ref-type="supplementary-material"}.

A total of 26 NUAT-NKTCL patients (28.3%) received RT for primary treatment, which was significantly less than UAT-NKTCL patients (69.0%, p \< 0.001). RT was administered as a consolidative therapy following complete remission (CR) to CT in nine patients with radiation fields covering the primary area of disease, 12 patients received RT to the residual lesions after partial remission (PR) to CT, and 2 patients received RT after stable disease (SD) to CT. For 14 patients who had PR or SD, RT improved the response to CR in six patients (42.9%). RT was administered with a median dose of 50.0 Gy (range, 20.0 to 56.0 Gy). Six patients were irradiated using conventional two-dimensional techniques, eight patients received intensity-modulated radiotherapy, and two patients received three-dimensional conformal radiotherapy.

Treatment response of different treatment modalities in NUAT-NKTCL and UAT-NKTCL patients were shown in [S3 Table](#SD3-crt-2018-681){ref-type="supplementary-material"}. Among the 90 NUAT-NKTCL patients who received anti-tumor treatment, CR, PR, SD, and progressive disease were observed after primary treatment in 39 (43.3%), 13 (14.4%), 6 (6.7%), and 28 (31.1%) patients, respectively and unknown in 4 patients (4.4%). The CR rate between patients treated with ASP-containing and ASP-absent regimens was not statistically different (48.3% vs. 38.5%, p=0.398). The overall response rate (ORR) of the ASP-containing regimens tended to be higher than ASP-absent regimens, although the difference was not statistically different (66.7% vs. 46.2%, p=0.074). Receiving RT as part of the primary treatment was associated with a significantly higher ORR (80.8% vs. 51.7%, p=0.011), but not a significantly higher CR rate (57.7% vs. 40.0%, p=0.130).

3. Survival and prognostic factors
----------------------------------

The median follow-up time was 26.3 months (range, 0.2 to 250.4 months) for all surviving individuals. At the end of last follow-up, 49 NUAT-NKTCL patients (53.3%) and 213 UAT-NKTCL patients (32.0%) had died. The 5-year OS for NUAT-NKTCL and UAT-NKTCL were 34.7% and 64.2%, respectively, which was significantly different (p \< 0.001) ([Fig. 1](#f1-crt-2018-681){ref-type="fig"}). And the 5-year PFS rates for NUAT-NKTCL and UAT-NKTCL were 56.1% and 20.2%, respectively, which was also significantly different (p \< 0.001) ([Fig. 1](#f1-crt-2018-681){ref-type="fig"}). The median OS and PFS duration for NUAT-NKTCL were 30.9 and 12.7 months, respectively, while the median OS and PFS duration for NUAT-NKTCL were not reached and 95.4 months.

Results of univariate analysis in NUAT-NKTCL are summarized in [Table 3](#t3-crt-2018-681){ref-type="table"}. We found that patients with B symptoms, elevated serum LDH, extranodal sites involvement ≥ 2, presence of hemophagocytosis, IPI score ≥ 3 or PINK score ≥ 3 ([Fig. 2A](#f2-crt-2018-681){ref-type="fig"} and [B](#f2-crt-2018-681){ref-type="fig"}) had significantly worse OS, whereas those with B symptoms and presence of hemophagocytosis had significantly worse PFS, compared with their counterparts ([Table 3](#t3-crt-2018-681){ref-type="table"}). Different from UAT-NKTCL, Ann Arbor stage system failed to predict OS or PFS in NUAT-NKTCL ([Fig. 3](#f3-crt-2018-681){ref-type="fig"}). Patients who received RT had a significantly longer PFS (hazard ratio \[HR\], 0.478; 95% confidence interval \[CI\], 0.265 to 0.861; p= 0.014) but not a significantly better OS (HR, 0.634; 95% CI, 0.328 to 1.224; p=0.174). Patients treated with chemotherapeutic regimens containing ASP tended to have a better OS (HR, 0.601; 95% CI, 0.332 to 1.089; p=0.093) and PFS (HR, 0.673; 95% CI, 0.397 to 1.142; p=0.142), although the differences were not significantly different. Patients who achieved CR after primary treatment had significantly better OS and PFS than those did not, both with p-value of \< 0.001.

In [Table 4](#t4-crt-2018-681){ref-type="table"}, multivariate analysis showed that B symptoms (HR, 1.984; 95% CI, 1.005 to 3.916; p=0.048) and elevated LDH levels (HR, 2.147; 95% CI, 1.067 to 4.319; p=0.032) were both independently associated with worse OS. Presence of B symptoms independently correlated with worse PFS (HR, 2.040; 95% CI, 1.137 to 3.661; p=0.017).

Discussion
==========

NUAT-NKTCL was considered as a unique subtype of NKTCL since heterogeneity was found between UAT-NKTCL and NUAT-NKTCL in several previous studies \[[@b2-crt-2018-681]-[@b10-crt-2018-681]\], in aspects of clinical characteristics, treatment response, prognostic factors, and longterm survival. In this retrospective single-center study, we comprehensively analyzed clinical data of patients diagnosed with NUAT-NKTCL from 2001 to 2017, aiming to provide a better understanding of this entity.

The most common site of NUAT-NKTCL was the skin and soft tissue (n=42, 45.7%), which was consistent with results of published literature \[[@b3-crt-2018-681],[@b5-crt-2018-681],[@b7-crt-2018-681]-[@b10-crt-2018-681],[@b16-crt-2018-681]-[@b19-crt-2018-681]\]. NUAT-NKTCL patients had a male to female ratio of 1.7:1 and the median age of 35 years at diagnosis with 13.0% were older than 60, which were similar to UAT-NKTCL patients. Similarly, several studies had found no obvious difference between UAT-NKTCL and NUAT-NKTCL in terms of sex and age \[[@b2-crt-2018-681],[@b4-crt-2018-681],[@b7-crt-2018-681],[@b8-crt-2018-681],[@b10-crt-2018-681],[@b20-crt-2018-681]\]. Overall, the NUAT-NKTCL cohort in this study presented with a high-risk clinical profile. Consistent with results of previous studies, we found that more NUAT-NKTCL patients had ECOG scores ≥ 2 (42.4%) \[[@b2-crt-2018-681]-[@b5-crt-2018-681],[@b10-crt-2018-681]\], involvement of regional lymph nodes (51.7%) \[[@b3-crt-2018-681],[@b5-crt-2018-681],[@b7-crt-2018-681]\], involvement of distant lymph nodes (28.1%), ≥ 2 extranodal sites (44.0%) \[[@b3-crt-2018-681],[@b5-crt-2018-681],[@b7-crt-2018-681],[@b9-crt-2018-681]\], involvement of bone marrow (11.0%), elevated serum LDH (55.4%) \[[@b2-crt-2018-681]-[@b4-crt-2018-681],[@b7-crt-2018-681],[@b9-crt-2018-681],[@b10-crt-2018-681]\], IPI score ≥ 3 (50.0%) \[[@b4-crt-2018-681]-[@b7-crt-2018-681],[@b9-crt-2018-681],[@b10-crt-2018-681]\], PINK score ≥ 3 (36.3%) \[[@b21-crt-2018-681]\], and Ann Arbor stage III/IV (64.8%) \[[@b2-crt-2018-681]-[@b10-crt-2018-681],[@b22-crt-2018-681]\]. The median of Ki-67 index was 70% for NUAT-NKTCL patients, which was significantly higher than UAT-NKTCL (60%) and indicated highly malignant features \[[@b8-crt-2018-681],[@b9-crt-2018-681]\]. In conclusion, patients with NUAT-NKTCL had worse performance status, more unfavorable prognostic factors, and more advanced stage.

Ann Arbor stage was proved to be an independent prognostic factor of long term survival for NKTCL patients in most studies. However, we found that Ann Arbor stage could not predict OS or PFS for NUAT-NKTCL patients. An explanation for this phenomenon is that nearly half of cases originated at the skin and soft tissues, which were often staged as stage III or IV in the Ann Arbor stage system although some had relatively favorable clinical outcomes. Published researches had confirmed the prognostic values of IPI score and PINK score in NKTCL \[[@b21-crt-2018-681],[@b23-crt-2018-681]\]. Although both of them could not significantly discriminate every risk subgroup, high-intermediate risk group (IPI score=3) and high risk group (IPI score=4, 5) of IPI, and 3 or 4 risk factors of PINK predicted worse OS.

Approximately 70% of NUAT-NKTCL patients were treated with CT alone as primary treatment and only about 30% received RT, which was different from UAT-NKTCL (only 29.0% accepted CT alone, p \< 0.001) and in accord with results of previous studies \[[@b2-crt-2018-681],[@b3-crt-2018-681],[@b7-crt-2018-681],[@b22-crt-2018-681]\]. The proportion of RT administration between NUAT-NKTCL patients with limited and advanced-stage disease was also significantly different (46.9% vs. 18.6%, p \< 0.001). More advanced stage patients of NUAT-NKTCL somehow explained the much lower proportion of RT administration, compared with UAT-NKTCL. On the other hand, a curative dose of RT (usually 50 Gy) may not be suitable for some specific sites of primary lesion in NUAT-NKTCL, such as the lungs, the GI tract, etc. According to present evidences, UAT-NKTCL is sensitive to RT and has a CR rate of 70% to 90% for limited-stage disease \[[@b24-crt-2018-681]-[@b28-crt-2018-681]\]. We also found that a CR rate of 90.5% (362 of 400) in limited-stage UAT-NKTCL patients whose treatment response could be evaluated. However, the CR rate in limited-stage NUAT-NKTCL patients was only 66.7% (10 of 15), which was significantly lower (p=0.003). Besides, receiving RT as part of the primary treatment did not significantly influence the CR rate or OS, although it did improve the ORR and PFS. Considering the above results, the sensitivity of NUAT-NKTCL to irradiation may need further exploring. The CR rate and the ORR were 40.0% and 51.7% respectively in pati-ents received CT alone as primary treatment. Patients treated with ASP-containing regimens tended to have higher ORR and CR rate. CT should still be recommended in most NUAT-NKTCL patients considering the high percentage of advanced-stage disease.

Univariate analysis found that patients with B symptoms, elevated serum LDH levels, extranodal sites involvement ≥ 2, and the presence of hemophagocytosis had significantly worse OS, whereas those with B symptoms or presence of hemophagocytosis had significantly worse PFS. High IPI scores (≥ 3) and high PINK scores (≥ 3) both correlate with worse OS. Administration of RT in primary therapy significantly improved PFS but not OS. ASP-containing regimens tended to be associated with better OS and PFS. Patients achieved CR after primary treatment had significantly longer OS and PFS. According to previous studies, these prognostic factors are closely relevant to each other, which might result in misleading interpretations of their prognostic values. Thus we subsequently conducted a multivariate analysis to find independent prognostic factors for NUAT-NKTCL. We found that B symptoms and elevated serum LDH levels were significantly correlated with worse OS, and presence of B symptoms also predicted shorter PFS.

The 5-year OS for NUAT-NKTCL was 34.7% and the median OS duration was 30.9 months, which were better than results of previous studies \[[@b2-crt-2018-681]-[@b10-crt-2018-681],[@b16-crt-2018-681],[@b29-crt-2018-681],[@b30-crt-2018-681]\]. This might be attributed to the development of therapeutic methods and the improvement of supportive care during recent years. However, long-term survival of NUAT-NKTCL was still much worse than UAT-NKTCL.

There are limitations due to the retrospective nature of our study. Patients with lesions located in both the UAT and NUAT sites at initial presentation were classified as UAT-NKTCL in our analysis. Some patients were treated with diverse chemotherapeutic regimens in primary treatment. Moreover, some important data were not available for every patient, such as serum LDH, plasma EBV DNA copy number, and so on. Further efforts should be made to focus on the improvement of treatment and survival for NUAT-NKTCL in large scale multicenter studies.

In conclusion, NUAT-NKTCL is a distinctive subtype of NKTCL in many aspects. Patients with NUAT-NKTCL have relatively poorer performance status, more unfavorable prognostic factors, more advanced stage, and poorer prognosis.
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###### 

The clinical characteristics of patients with NUAT-NKTCL and UAT-NKTCL

  Parameter                                                                                NUAT              UAT               p-value
  ---------------------------------------------------------------------------------------- ----------------- ----------------- ----------
  **Overall**                                                                              92 (100)          665 (100)         
  **Sex**                                                                                                                      
   Male                                                                                    58 (63.0)         463 (69.6)        0.202
   Female                                                                                  34 (37.0)         202 (30.4)        
  **Age (yr)**                                                                                                                 
   Median (range)                                                                          35 (1-79)         43 (3-80)         0.004
   ≤ 60                                                                                    80 (87.0)         583 (87.7)        0.846
   \> 60                                                                                   12 (13.0)         82 (12.3)         
  **ECOG score**                                                                                                               
   0-1                                                                                     53 (57.6)         577 (86.8)        \< 0.001
   ≥ 2                                                                                     39 (42.4)         69 (10.4)         
   Unknown                                                                                 0                 19 (2.9)          
  **B symptoms^[a)](#tfn1-crt-2018-681){ref-type="table-fn"}^**                            48 (52.7)         344 (52.4)        0.956
  **Involvement of regional lymph nodes^[b)](#tfn2-crt-2018-681){ref-type="table-fn"}^**   45 (51.7)         242 (36.9)        0.008
  **Involvement of distant lymph nodes^[c)](#tfn3-crt-2018-681){ref-type="table-fn"}^**    25 (28.1)         64 (9.8)          \< 0.001
  **Extranodal sites involvement ≥ 2^[d)](#tfn4-crt-2018-681){ref-type="table-fn"}^**      40 (44.0)         81 (12.4)         \< 0.001
  **Involvement of bone marrowd)**                                                         10 (11.0)         13 (2.0)          \< 0.001
  **Presence of hemophagocytosis**                                                         7 (7.6)           38 (5.7)          0.471
  **Ann Arbor stage**                                                                                                          
   I-II                                                                                    32 (34.8)         557 (83.8)        \< 0.001
   III-IV                                                                                  59 (64.1)         99 (14.9)         
   Unknown                                                                                 1 (1.1)           9 (1.4)           
  **Elevated LDH^[e)](#tfn5-crt-2018-681){ref-type="table-fn"}^**                          41 (55.4)         169 (28.5)        \< 0.001
  **EBV DNA in blood**                                                                                                         
   Detectable                                                                              28 (30.4)         216 (32.5)        0.093
   Undetectable                                                                            15 (16.3)         166 (25.0)        
   Unknown                                                                                 49 (53.3)         283 (42.6)        
  **Median Ki-67 index (range, %)^[f)](#tfn6-crt-2018-681){ref-type="table-fn"}^**         70 (15-100)       60 (5-100)        \< 0.001
  **Median SUVmax (range)^[g)](#tfn7-crt-2018-681){ref-type="table-fn"}^**                 14.6 (2.7-29.3)   13.9 (2.0-79.4)   0.924
  **IPI score**                                                                                                                
   0-1                                                                                     21 (22.8)         476 (71.6)        \< 0.001
   2                                                                                       19 (20.7)         36 (5.4)          
   3                                                                                       28 (30.4)         46 (6.9)          
   4-5                                                                                     12 (13.0)         27 (4.1)          
   Unknown                                                                                 12 (13.0)         80 (12.0)         
  **PINK score**                                                                                                               
   0                                                                                       0                 475 (71.4)        \< 0.001
   1                                                                                       24 (26.1)         104 (15.6)        
   2                                                                                       33 (35.9)         62 (9.3)          
   3-4                                                                                     33 (35.9)         11 (1.7)          
   Unknown                                                                                 1 (1.1)           13 (2.0)          
  **Treatment modalities**                                                                                                     
   CT alone                                                                                64 (69.6)         193 (29.0)        \< 0.001
   RT alone                                                                                0                 19 (2.9)          
   CT+RT                                                                                   19 (20.7)         309 (46.5)        
   RT+CT                                                                                   3 (3.3)           17 (2.6)          
   Sandwich chemoradiation                                                                 4 (4.3)           114 (17.1)        
   Supportive care                                                                         2 (2.2)           13 (2.0)          

Values are presented as number (%). NUAT, non-upper aerodigestive tract; NKTCL, natural killer/T-cell lymphoma; UAT, upper aerodigestive tract; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus; SUVmax, the maximal standardized uptake value; IPI, International Prognostic Index; PINK, Prognostic Index of Natural Killer Lymphoma; CT, chemotherapy; RT, radiotherapy.

Data was available in 747 patients,

Data was available in 742 patients,

Data was available in 743 patients,

Data was available in 745 patients,

Data was available in 667 patients,

Data was available in 519 patients,

Data was available in 318 patients.

###### 

Treatment modalities of patients with NK/T-cell lymphoma of non-upper aerodigestive tract

  Treatment                 Total      CT alone    CT+RT       RT+CT      Sandwich chemoradiation   Supportive care
  ------------------------- ---------- ----------- ----------- ---------- ------------------------- -----------------
  **All patients**          92 (100)   64 (69.6)   19 (20.7)   3 (3.3)    4 (4.3)                   2 (2.2)
   Stage I-II               32 (100)   16 (50.0)   13 (40.6)   1 (3.1)    1 (3.1)                   1 (3.1)
   Stage III-IV             59 (100)   47 (79.7)   6 (10.2)    2 (3.4)    3 (5.1)                   1 (1.7)
   Unknown                  1 (100)    1 (100)     0           0          0                         0
  **Primary sites**                                                                                 
   Skin and soft tissue     42 (100)   26 (61.9)   11 (26.2)   2 (4.8)    3 (7.1)                   0
   Gastrointestinal tract   18 (100)   16 (88.9)   1 (5.6)     0          0                         1 (5.6)
   Eye and adnexa           14 (100)   7 (50.0)    6 (42.9)    0          0                         1 (7.1)
   Spleen                   4 (100)    4 (100)     0           0          0                         0
   Testicle and ovary       5 (100)    4 (80.0)    0           0          1 (20.0)                  0
   Adrenal gland            2 (100)    1 (50.0)    1 (50.0)    0          0                         0
   Central nervous system   2 (100)    1 (50.0)    0           1 (50.0)   0                         0
   Lung and trachea         2 (100)    2 (100)     0           0          0                         0
   Unclassifiable           3 (100)    3 (100)     0           0          0                         0

Values are presented as number (%). NK, natural killer; CT, chemotherapy; RT, radiotherapy.

###### 

Univariate analysis of prognostic factors in patients with NK/T-cell lymphoma of non-upper aerodigestive tract

  Variable                                                    OS                     PFS                              
  ----------------------------------------------------------- ---------------------- ---------- --------------------- ----------
  Sex (female vs. male)                                       0.730 (0.394-1.351)    0.316      0.735 (0.430-1.258)   0.261
  Age (\> 60 yr vs. ≤60 yr)                                   1.482 (0.657-3.341)    0.343      1.024 (0.483-2.168)   0.951
  ECOG score (≥ 2 vs. 0-1)                                    1.219 (0.690-2.154)    0.495      1.432 (0.870-2.359)   0.158
  Stage (III-IV vs. I-II)                                     1.457 (0.876-2.423)    0.147      1.012 (0.639-1.604)   0.958
  B symptoms (yes vs. no)                                     2.019 (1.100-3.703)    0.023      1.902 (1.128-3.207)   0.016
  LDH (elevated vs. normal)                                   2.396 (1.198-4.789)    0.013      1.458 (0.822-2.587)   0.197
  Involvement of regional lymph nodes                         1.344 (0.736-2.454)    0.336      0.998 (0.591-1.687)   0.995
  Involvement of distant lymph nodes                          1.521 (0.790-2.928)    0.209      1.127 (0.634-2.006)   0.683
  Extranodal sites involvement (≥ 2 vs. 0-1)                  1.974 (1.094-3.564)    0.024      1.263 (0.758-2.105)   0.371
  Involvement of bone marrow                                  2.014 (0.842-4.817)    0.116      1.497 (0.677-3.312)   0.319
  Presence of hemophagocytosis                                4.363 (1.776-10.717)   0.001      2.766 (1.156-6.616)   0.022
  IPI score (3-5 vs. 0-2)                                     2.850 (1.490-5.451)    0.002      1.498 (0.870-2.580)   0.145
  PINK score (3-4 vs. 1-2)                                    2.065 (1.133-3.764)    0.018      1.153 (0.681-1.953)   0.595
  Treatment (RT vs. no RT)                                    0.634 (0.328-1.224)    0.174      0.478 (0.265-0.861)   0.014
  Chemotherapeutic regimens (ASP-containing vs. ASP-absent)   0.601 (0.332-1.089)    0.093      0.673 (0.397-1.142)   0.142
  Treatment response (CR vs. no CR)                           0.289 (0.151-0.553)    \< 0.001   0.200 (0.111-0.358)   \< 0.001

NK, natural killer; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; PINK, Prognostic Index of Natural Killer Lymphoma; RT, radiotherapy; ASP, asparaginase; CR, complete remission.

###### 

Multivariate analysis of prognostic factors in patients with NK/T-cell lymphoma of non-upper aerodigestive tract

  Variable                                     OS                    PFS                           
  -------------------------------------------- --------------------- ------- --------------------- -------
  Age (\> 60 yr vs. ≤ 60 yr)                   \-                    \-      \-                    \-
  ECOG score (≥ 2 vs. 0-1)                     \-                    \-      \-                    \-
  Stage (III-IV vs. I-II)                      \-                    \-      \-                    \-
  B symptoms (yes vs. no)                      1.984 (1.005-3.916)   0.048   2.040 (1.137-3.661)   0.017
  LDH (elevated vs. normal)                    2.147 (1.067-4.319)   0.032   \-                    \-
  Extranodal sites involvement (≥ 2 vs. 0-1)   \-                    \-      \-                    \-
  Presence of hemophagocytosis                 \-                    \-      \-                    \-

The hazard ratio gives the increase in risk for each unit increase for the continuous variables and gives the increased risk relative to the reference category for the categorical variables. NK, natural killer; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
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